A micro-electroporation/electrophoresis-based vaccine screening system reveals the impact of vaccination orders on cross-protective immunity
Brief intro:
- Author: Yongyong Li, Jingshan Mo, Jing Liu, Ying Liang, Caiguanxi Deng, Zhangping Huang, Juan Jiang, Ming Liu, Xinmin Liu, Liru Shang, Xiafeng Wang, Xi Xie, Ji Wang
- Journal: iScience
- Doi: https://www.doi.org/10.1016/j.isci.2023.108086
- Publication Date: 2023 Sep 27
Products/Services used in the paper
Quotation shows PackGene:Human ACE2 overexpression stable HEK293T (hACE2-293T, PackGene Biotech) cells were cultured under an atmosphere of 5% CO2 at 37°C in Dulbecco’s modified Eagle’s medium (DMEM, #10-013-CVRC, Corining) supplemented with 10% inactivated FEB (#FSP500, ExCellBio), non-essential amino acids (NEAA, #11140-050, Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin (#SV30010, HyClone).
Research Field:DNA Vaccine
Targeted organ:blood, liver
Animal or cell line strain:mouse
Abstract
The constant emergence of mutated pathogens poses great challenges to the existing vaccine system. A screening system is needed to screen for antigen designs and vaccination strategies capable of inducing cross-protective immunity. Herein, we report a screening system based on DNA vaccines and a micro-electroporation/electrophoresis system (MEES), which greatly improved the efficacy of DNA vaccines, elevating humoral and cellular immune responses by over 400- and 35-fold respectively. Eighteen vaccination strategies were screened simultaneously by sequential immunization with vaccines derived from wildtype (WT) SARS-CoV-2, Delta, or Omicron BA.1 variant. Sequential vaccination of BA.1-WT-Delta vaccines with MEES induced potent neutralizing antibodies against all three viral strains and BA.5 variant, demonstrating that cross-protective immunity against future mutants can be successfully induced by existing strain-derived vaccines when a proper combination and order of sequential vaccination are used. Our screening system could be used for fast-seeking vaccination strategies for emerging pathogens in the future.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
